Back to Results
First PageMeta Content
Health / Chugai Pharmaceutical Co. / Ibandronic acid / Anatomy / Taisho Pharmaceutical Co. / Bone density / Medicine / Bisphosphonates / Osteopathies / Osteoporosis


Translation Taisho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. New Drug Application Filed for Ibandronate Sodium Hydrate Oral Agent, Bisphosphonate Antiresorptive Agent
Add to Reading List

Document Date: 2015-02-10 01:01:03

Open Document

File Size: 16,35 KB

Share Result on Facebook

City

Tokyo / Basel / /

Company

Chugai Pharmaceutical Co. Ltd. / Taisho Pharmaceutical Co. Ltd. / Translation Taisho Pharmaceutical Co. Ltd. / Taisho Toyama Pharmaceutical Co. Ltd. / F. Hoffmann-La Roche Ltd. / /

Country

Switzerland / Japan / United States / /

Event

FDA Phase / /

IndustryTerm

osteoporosis treatment / healthcare professionals / prevention of osteoporosis / treatment of osteoporosis / /

MedicalCondition

osteoporosis / /

Organization

Ministry of Health / /

Person

Akira Ohira / Osamu Nagayama / Shigeru Uehara / /

Position

CEO / President / Head Office / Chairman & CEO / /

Product

Boniva / RG484 oral / Bonviva® IV Injection / Bisphosphonate Antiresorptive Agent / Ibandronate Sodium Hydrate Oral Agent / /

SocialTag